基本信息
浏览量:2
职业迁徙
个人简介
Dr. Paul Fletcher is Senior Scientist and Head of Biopsychology in the Campbell Family Mental Health Research Institute at CAMH. He is Professor of Psychology at the University of Toronto.
Dr. Fletcher and his team use preclinical models to investigate the neurochemical bases of behaviours relevant to addictions and psychiatric disorders, and to identify the mechanisms of action of drugs used to treat these disorders. Current research under Dr. Fletcher’s direction has:
1. Demonstrated differing roles of two serotonin receptor subtypes (5-HT2A and 5-HT2C) in modulating effects of cocaine, and perhaps other drugs of abuse. For example, activating the 5-HT2C receptor reduces the locomotor stimulant and reinforcing effects of cocaine, while blocking this receptor leads to the opposite profile of effects. These data implicate the 5-HT2C receptor in particular as a contributory factor in the development of addiction, and suggest that this might be a fruitful target for treating addiction.
2. Shown that depletion of serotonin in the nucleus accumbens, but not the prefrontal cortex, leads to difficulties in inhibiting responding. In collaboration with Dr. Guy Higgins (NPS Pharmaceuticals in Salt Lake City, Utah), we have found that 5-HT2A receptor antagonists reduce such impulsive-like behaviour, but 5-HT2C receptor antagonists enhance this behaviour. Overall, our findings suggest that the relationship between 5-HT activity and impulsivity is complex, and may depend on which brain areas and which receptor subtypes are affected.
3. Shown that the amphetamine-induced sensitised state (AISS) also leads to cognitive deficits that are similar to those observed in schizophrenia. The most pronounced deficits are in sustained visual attention, and attentional set-shifting. Both of these deficits are reversed by infusing a dopamine D1 receptor agonist into the prefrontal cortex. Our future plans involve using this model to test potential treatments, including D1 receptor agonists, for cognitive disturbances in schizophrenia.
Dr. Fletcher and his team use preclinical models to investigate the neurochemical bases of behaviours relevant to addictions and psychiatric disorders, and to identify the mechanisms of action of drugs used to treat these disorders. Current research under Dr. Fletcher’s direction has:
1. Demonstrated differing roles of two serotonin receptor subtypes (5-HT2A and 5-HT2C) in modulating effects of cocaine, and perhaps other drugs of abuse. For example, activating the 5-HT2C receptor reduces the locomotor stimulant and reinforcing effects of cocaine, while blocking this receptor leads to the opposite profile of effects. These data implicate the 5-HT2C receptor in particular as a contributory factor in the development of addiction, and suggest that this might be a fruitful target for treating addiction.
2. Shown that depletion of serotonin in the nucleus accumbens, but not the prefrontal cortex, leads to difficulties in inhibiting responding. In collaboration with Dr. Guy Higgins (NPS Pharmaceuticals in Salt Lake City, Utah), we have found that 5-HT2A receptor antagonists reduce such impulsive-like behaviour, but 5-HT2C receptor antagonists enhance this behaviour. Overall, our findings suggest that the relationship between 5-HT activity and impulsivity is complex, and may depend on which brain areas and which receptor subtypes are affected.
3. Shown that the amphetamine-induced sensitised state (AISS) also leads to cognitive deficits that are similar to those observed in schizophrenia. The most pronounced deficits are in sustained visual attention, and attentional set-shifting. Both of these deficits are reversed by infusing a dopamine D1 receptor agonist into the prefrontal cortex. Our future plans involve using this model to test potential treatments, including D1 receptor agonists, for cognitive disturbances in schizophrenia.
研究兴趣
论文共 264 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2024)
Pharmacology Biochemistry and Behavior (2024): 173703
引用0浏览0引用
0
0
Pharmacology, biochemistry, and behavior (2023): 173703-173703
Behavioural brain research (2023): 114438-114438
SCHIZOPHRENIAno. 1 (2022): 85
Neuropharmacology (2022): 109150-109150
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn